![Calixar invests €1 Million in pipeline of highly druggable membrane protein targets and native antigens](https://ala.associates/wp-content/uploads/2021/04/Calixar-pipeline-500x250-1.jpg)
![Calixar invests €1 Million in pipeline of highly druggable membrane protein targets and native antigens](https://ala.associates/wp-content/uploads/2021/04/Calixar-pipeline-500x250-1.jpg)
![Domain Therapeutics presents most recent developments of its BRET technology portfolio at AACR and ASPET events](https://ala.associates/wp-content/uploads/2021/04/Pascal-NEUVILLE_DOMAIN-Therapeutics_portrait-6-1-895x675.png)
Domain Therapeutics presents most recent developments of its BRET technology portfolio at AACR and ASPET events
![Yposkesi to give talk on gene therapy vectors at Virtual Cell & Gene Meeting on the Mediterranean, April 6 – 9, 2021](https://ala.associates/wp-content/uploads/2021/03/YPK-Cell-presentation.png)
Yposkesi to give talk on gene therapy vectors at Virtual Cell & Gene Meeting on the Mediterranean, April 6 – 9, 2021
![Cell-Easy strengthens executive team with two new highly experienced members](https://ala.associates/wp-content/uploads/2021/03/2021-03-23-Cell-Easy-Photos-G-Lay-J-Bedier-3-1080x675.jpg)
Cell-Easy strengthens executive team with two new highly experienced members
![Chiesi and Hephaï join forces to develop AI educational tool to improve inhaler use](https://ala.associates/wp-content/uploads/2021/03/Valery-Trosini-Desert-Hephai.jpeg)
Chiesi and Hephaï join forces to develop AI educational tool to improve inhaler use
![OncoDiag raises €2.5M ($3M) to develop its diagnostic testing for early detection of cancer](https://ala.associates/wp-content/uploads/2021/03/Claude-Hennion-OncoDiag-1080x675.jpg)
OncoDiag raises €2.5M ($3M) to develop its diagnostic testing for early detection of cancer
![Tollys welcomes Dr. Jean-Pierre Armand as member of its scientific advisory board](https://ala.associates/wp-content/uploads/2021/03/TOLLYS-JP-Armand.jpg)
Tollys welcomes Dr. Jean-Pierre Armand as member of its scientific advisory board
![CVasThera secures €1.3 Million in first funding round](https://ala.associates/wp-content/uploads/2021/03/DSC_1892-1080x675.jpg)
CVasThera secures €1.3 Million in first funding round
![Accure Therapeutics enrols first patient in phase II clinical trial on acute optic neuritis with lead candidate ACT-01](https://ala.associates/wp-content/uploads/2021/03/medori-photo-002-746x675.jpg)
Accure Therapeutics enrols first patient in phase II clinical trial on acute optic neuritis with lead candidate ACT-01
![Biomunex Pharmaceuticals signs strategic license and co-development agreement with Onward Therapeutics for proprietary bispecific antibody program](https://ala.associates/wp-content/uploads/2021/02/Sans-titre-4-1080x675.png)